Citations

Clear

3942 citation(s) found for "To, Van".

P433 Short-term outcomes of surgical treatment in primary ileocecal Crohn’s disease patients. Results of Crohn’s(urg) study, multicenter, retrospective, comparative analysis between indications for luminal and complicated phenotype
Bislenghi, Gabriele , D’Hoore, André , Juachon, Patrizia, Harsløf, Sanne , Gomez, Joanne Michelle D. , Merchea, Amit , Shacker, A, Gallostra, M Marti, Maruyana, B Yuki, Garoufalia, Zoe , Zhihui, C, Rrupa, Djana , Haanappel, Anouck , Giorgi, Lorenzo , Avellaneda, Nicolás , Pellino, Gianluca , Maroli, Annalisa , Tottrup, A, Colpaert, J, Giorgi, L, Overstraeten, Anthony de Buck van , Olivera, Pablo Andres , Gomez, J, Holubar, Stefan D. , Lincango-Naranjo, Eddy , Steele, Scott R. , Gallostra, M Marti, Kraft, Miquel , Kotze, Paulo Gustavo , Wexner, Steven D. , Zhihui, C, Hahnloser, Dieter , Buskens, Christianne Johanna , Warusavitarne, Janindra H. , Williams, K, Christensen, Peter , Spinelli, Antonino

Mayo Clinic

Journal of Crohn's and Colitis | January 24, 2024 | Volume: 18 | Issue: Supplement_1 | Pages: i881-i883

10.1093/ecco-jcc/jjad212.0563 Get It

Abstract Background Recent evidence challenges the current standard of offering surgery to patients with ileocecal Crohn’s disease only when they present complications of the disease. Methods A retrospective, multicenter comparative analysis was performed including patients operated for primary ileocecal CD at 12 referral centers. Patients were divided in 2 groups, according to indication of surgery for inflammatory (ICD) or complicated (CCD) phenotype. Short-term results were compared. Patients operated on for primary isolated ileocaecal CD (last 50 cm of the terminal ileum and cecum), either for predominantly inflammatory phenotype or for complications of the disease (stricturing or fistulizing pattern), between January 2012 - December 2021 were considered eligible to participate in this study. Patients with previous abdominal procedures for CD, and patients who had activity of the disease in other intestinal segments other than the ileocaecal region at the time of surgery, were excluded from the study. Results 2013 patients were included, 291 (14.5%) in the ICD group. No differences were found between groups in time from diagnosis to surgery or in the levels of exposure to biologic drugs before indication of surgery. CCD patients had higher rates of low BMI, anemia (40.9 vs. 27%, p: < 0.001), and low albumin (11.3 vs. 2.6%, p: < 0.001). CCD patients had longer operations, lower rates of laparoscopic approach (84.3 vs. 93.1%, p: 0.001), and higher conversion rates (9.3 vs. 1.9%, p: < 0.001). CCD had longer hospital stay and higher postoperative complication rates (26.1 vs. 21.3%, p: 0.083). Anastomotic leakage and reoperations were also more frequent in this group. More patients in the CCD group required an extended bowel resection (14.1 vs. 8.3%, p: 0.017). In multivariate analysis, CCD was associated with prolonged surgeries (OR: 3.44, p: 0.001) and requirements of multiple intraoperative procedures (OR: 8.39, p: 0.030). Conclusion Indication of surgery in patients who present an inflammatory phenotype of CD was associated with better outcomes when compared to patients operated on for complications of the disease, without a difference between groups in time from diagnosis to surgery.
Small RNA Changes in Plasma Have Potential for Early Diagnosis of Alzheimer’s Disease before Symptom Onset
Palade, Joanna , Alsop, Eric , Courtright-Lim, Amanda , Keuren‐Jensen, Kendall Van , Palade, Joanna , Hsieh, Michael, Whitsett, Timothy G. , Galasko, Douglas

Mayo Clinic

Cells | January 23, 2024 | Volume: 13 | Issue: 3 | Pages: 207

10.3390/cells13030207 | PMID 38334599 Get It

Alzheimer’s disease (AD), due to its multifactorial nature and complex etiology, poses challenges for research, diagnosis, and treatment, and impacts millions worldwide. To address the need for minimally invasive, repeatable measures that aid in AD diagnosis and progression monitoring, studies leveraging RNAs associated with extracellular vesicles (EVs) in human biofluids have revealed AD-associated changes. However, the validation of AD biomarkers has suffered from the collection of samples from differing points in the disease time course or a lack of confirmed AD diagnoses. Here, we integrate clinical diagnosis and postmortem pathology data to form more accurate experimental groups and use small RNA sequencing to show that EVs from plasma can serve as a potential source of RNAs that reflect disease-related changes. Importantly, we demonstrated that these changes are identifiable in the EVs of preclinical patients, years before symptom manifestation, and that machine learning models based on differentially expressed RNAs can help predict disease conversion or progression. This research offers critical insight into early disease biomarkers and underscores the significance of accounting for disease progression and pathology in human AD studies.
Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM+NABP) in patients who have not previously received chemotherapy for met
Chandana, Sreenivasa R , Pazo-Cid, Roberto , Dean, Andrew , Lee, Woo Jin , Goetze, Thorsten Oliver , Paulson, Andrew Scott , Pant, Shubham , Hubner, Richard , Xiao, Zhimin , Li, Jia , Benzaghou, Fawzi, Wainberg, Zev A. , Melisi, Davide , Macarulla, Teresa , Fouchardière, Christelle de la , Kišš, Igor , Cutsem, Eric Van , Bekaii‐Saab, Tanios , Pant, Shubham , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: 687-687

10.1200/jco.2024.42.3_suppl.687 Get It

687 Background: The NAPOLI 3 study (NCT04083235, N = 770) reported that NALIRIFOX improved overall survival (OS) vs Gem+NabP with manageable toxicity in 1L treatment of metastatic pancreatic adenocarcinoma. We explored changes in CA19-9 levels and their potential associations with efficacy as an important tumor marker in pancreatic adenocarcinoma. Methods: In NAPOLI 3, CA19-9 was evaluated at baseline and every 8 weeks until patients discontinued study treatment. The detection limit of CA19-9 was 8000 kU/L in this study. The Cox proportional hazards regression and logistic regression were employed to investigate the relationship between CA19-9 decrease and OS, progression-free survival (PFS), and overall response rate (ORR). Results: Patients with evaluable CA19-9 (levels =< 8000) at baseline and additional measurements at weeks 8 and 16 were included in the analysis (NALIRIFOX, n = 179; Gem+NabP, n = 194). The median baseline CA19-9 level was 378.0 and 409.7 kU/L for the NALIRIFOX and Gem+NabP arms, respectively. Overall, patients with (vs without) any CA 19-9 decrease by week 16 had a higher ORR (59.9% vs 35.2%; p = 0.002), a longer median PFS (9.2 vs 6.2 months; p < 0.001) and a longer median OS (14.2 vs 8.7 months; p = 0.005), respectively in a pooled analysis of the treatments. In the NALIRIFOX arm, patients with any CA19-9 decrease by week 16 had a higher confirmed ORR of 65.1% compared with those without at 42.4% ( p < 0.001), a median PFS of 9.5 vs 7.1 months ( p < 0.001) and a median OS of 15.4 versus 8.4 months ( p = 0.004), respectively. In the Gem+NabP arm, patients with CA19-9 decrease by week 16 had a higher ORR of 55.5% compared with those without at 23.8% ( p = 0.012), a median PFS of 7.6 versus 5.8 months ( p < 0.001) and a median OS of 13.7 versus 11.9 months ( p = 0.235), respectively. Conclusions: CA19-9 decrease by week 16 has the potential to be an early prognostic factor for OS, PFS and ORR. The results should be interpreted with caution as a considerable percentage of patients were excluded due to non-evaluable CA19-9 that exceeded the lab detection limit of 8000 kU/L. Clinical trial information: NCT04083235 .
Epidemiologic Factors in Relation to Colorectal Cancer Risk and Survival by Genotoxic Colibactin Mutational Signature
Thomas, Claire E. , Georgeson, Peter , Qu, Conghui , Steinfelder, Robert S. , Buchanan, Daniel D. , Song, Mingyang , Harrison, Tabitha A. , Um, Caroline Y. , Hullar, Meredith A.J. , Guelpen, Bethany Van , Huyghe, Jeroen R. , Aglago, Elom K. , Berndt, Sonja I. , Drew, David A. , Figueiredo, Jane C. , French, Amy J. , Giannakis, Marios , Goode, Ellen L. , Gruber, Stephen B. , Gsur, Andrea , Hoffmeister, Michael , Huang, Wen‐Yi , Newton, Christina C. , Obón‐Santacana, Mireia , Zaidi, Syed Hassan Ejaz , Peters, Ulrike , Phipps, Amanda I. , Hullar, Meredith A , Jenkins, Mark A , Van Guelpen, Bethany , Lynch, Brigid M , Melaku, Yohannes Adama , Huyghe, Jeroen R , Aglago, Elom K , Berndt, Sonja I , Boardman, Lisa , Campbell, Peter T , Cao, Yin , Chan, Andrew T , Drew, David A , Figueiredo, Jane C , Giannakis, Marios , Goode, Ellen L , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Hoffmeister, Michael , Hsu, Li , Huang, Wen-Yi , Moreno, Victor , Murphy, Neil , Newcomb, Polly A. , Newton, Christina C , Nowak, Jonathan A , Obón-Santacana, Mireia , Ogino, Shuji , Sun, Wei , Toland, Amanda Ewart , Trinh, Quang M , Ugai, Tomotaka , Zaidi, Syed H , Peters, Ulrike , Phipps, Amanda I , Buchanan, Daniel D , Harrison, Tabitha A , Um, Caroline Y , Song, Mingyang , Georgeson, Peter , Qu, Conghui , Steinfelder, Robert S , Thomas, Claire E , Jenkins, Mark A. , Boardman, Lisa A. , Campbell, Peter T. , Cao, Yin , Chan, Andrew T. , Gunter, Marc J. , Moreno, Vı́ctor , Murphy, Neil , Nowak, Jonathan A. , Sun, Wei , Trinh, Quang M.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 22, 2024 | Volume: 33 | Issue: 4 | Pages: 534-546

10.1158/1055-9965.epi-23-0600 | PMID 38252034 Get It

Abstract Background: The genotoxin colibactin causes a tumor single-base substitution (SBS) mutational signature, SBS88. It is unknown whether epidemiologic factors’ association with colorectal cancer risk and survival differs by SBS88. Methods: Within the Genetic Epidemiology of Colorectal Cancer Consortium and Colon Cancer Family Registry, we measured SBS88 in 4,308 microsatellite stable/microsatellite instability low tumors. Associations of epidemiologic factors with colorectal cancer risk by SBS88 were assessed using multinomial regression (N = 4,308 cases, 14,192 controls; cohort-only cases N = 1,911), and with colorectal cancer–specific survival using Cox proportional hazards regression (N = 3,465 cases). Results: 392 (9%) tumors were SBS88 positive. Among all cases, the highest quartile of fruit intake was associated with lower risk of SBS88-positive colorectal cancer than SBS88-negative colorectal cancer [odds ratio (OR) = 0.53, 95% confidence interval (CI) 0.37-0.76; OR = 0.75, 95% CI 0.66–0.85, respectively, Pheterogeneity = 0.047]. Among cohort studies, associations of body mass index (BMI), alcohol, and fruit intake with colorectal cancer risk differed by SBS88. BMI ≥30 kg/m2 was associated with worse colorectal cancer–specific survival among those SBS88-positive [hazard ratio (HR) = 3.40, 95% CI 1.47–7.84], but not among those SBS88-negative (HR = 0.97, 95% CI 0.78–1.21, Pheterogeneity = 0.066). Conclusions: Most epidemiologic factors did not differ by SBS88 for colorectal cancer risk or survival. Higher BMI may be associated with worse colorectal cancer–specific survival among those SBS88-positive; however, validation is needed in samples with whole-genome or whole-exome sequencing available. Impact: This study highlights the importance of identification of tumor phenotypes related to colorectal cancer and understanding potential heterogeneity for risk and survival.
Recommended implementation of quantitative susceptibility mapping for clinical research in the brain: A consensus of the ISMRM electro‐magnetic tissue properties study group
Bilgiç, Berkin , Costagli, Mauro , Chan, Kwok‐Shing , Duyn, Jeff H. , Lee, Jongho , Li, Xu , Liu, Chunlei , Marques, José P. , Schweser, Ferdinand , Straub, Sina , Group, ISMRM Electro‐Magnetic Tissue Properties Study, Bilgic, Berkin , Costagli, Mauro , Chan, Kwok-Shing , Langkammer, Christian , Lee, Jongho , Li, Xu , Liu, Chunlei , Marques, José P , Robinson, Simon Daniel , Schweser, Ferdinand , Shmueli, Karin , Spincemaille, Pascal , Straub, Sina , Milovic, Carlos , Spincemaille, Pascal , Zijl, Peter C.M. van , Wang, Yi , Group, ISMRM Electro‐Magnetic Tissue Properties Study

Mayo Clinic

Magnetic Resonance in Medicine | January 22, 2024 | Volume: 91 | Issue: 5 | Pages: 1834-1862

10.1002/mrm.30006 | PMID 38247051 Get It

AbstractThis article provides recommendations for implementing QSM for clinical brain research. It is a consensus of the International Society of Magnetic Resonance in Medicine, Electro‐Magnetic Tissue Properties Study Group. While QSM technical development continues to advance rapidly, the current QSM methods have been demonstrated to be repeatable and reproducible for generating quantitative tissue magnetic susceptibility maps in the brain. However, the many QSM approaches available have generated a need in the neuroimaging community for guidelines on implementation. This article outlines considerations and implementation recommendations for QSM data acquisition, processing, analysis, and publication. We recommend that data be acquired using a monopolar 3D multi‐echo gradient echo (GRE) sequence and that phase images be saved and exported in Digital Imaging and Communications in Medicine (DICOM) format and unwrapped using an exact unwrapping approach. Multi‐echo images should be combined before background field removal, and a brain mask created using a brain extraction tool with the incorporation of phase‐quality‐based masking. Background fields within the brain mask should be removed using a technique based on SHARP or PDF, and the optimization approach to dipole inversion should be employed with a sparsity‐based regularization. Susceptibility values should be measured relative to a specified reference, including the common reference region of the whole brain as a region of interest in the analysis. The minimum acquisition and processing details required when reporting QSM results are also provided. These recommendations should facilitate clinical QSM research and promote harmonized data acquisition, analysis, and reporting.
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Jahangir, Chowdhury Arif , Page, David B. , Broeckx, Glenn , Gonzalez, Claudia Aura, Burke, Caoimbhe, Murphy, Clodagh, Reis‐Filho, Jorge S. , Gupta, Rajarsi , Vieth, Michael, Hida, Akira I. , Kahila, Mohamed M. , Kos, Zuzana , Verbandt, Sara , Thagaard, Jeppe , Khiroya, Reena, Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Portela, Flávio Luis Dantas , Deman, Frederik , Dudgeon, Sarah , Elghazawy, Mahmoud , Fernandez‐Martín, Claudio , Fineberg, Susan , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hartman, Johan , Hewitt, Stephen M. , Husain, Zaheed, Irshad, Sheeba , Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Khramtsov, Andrey , Kirtani, Pawan , Korski, Konstanty, Scott, Ely, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Durga, Kharidehal, Mittal, Shachi , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Hytopoulos, Evangelos, Mahon, Sarah, Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Verghese, Gregory , Viale, Giuseppe , Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Bartlett, John M.S. , Loibl, Sibylle , Loi, Sherene , Stovgaard, Elisabeth Specht , Salgado, Roberto , Gupta, Rajarsi R , Chardas, Alexandros , Dantas Portela, Flavio Luis , Elghazawy, Mahmoud , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Hart, Steven N , Hartman, Johan , Kataoka, Tatsuki R , Rau, Tilman T , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Lennerz, Jochen , Loi, Sherene , Reis-Filho, Jorge S , Acs, Balazs , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , Ly, Amy , Harms, Paul W. , Diest, P. J. van , AbdulJabbar, Khalid , Adams, Sylvia , Almeida, Jonas S. , Ardalan, Farid Azmoudeh , Badve, Sunil , Hardas, Alexandros , Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Janssen, Emiel A. M. , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Aktürk, Güray , Kovács, Anikó , Lerousseau, Marvin , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Moore, David , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rajpoot, Nasir , Rapoport, Bernardo L. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sughayer, Maher A. , Sur, Daniel Genel , Symmans, W. Fraser , Teuwen, Jonas , Tran, William T, Laak, Jeroen van der , Yuan, Yinyin , Denkert, Carsten , Savas, Peter Stephen , Gallagher, William M. , Rahman, Arman

Mayo Clinic

The Journal of Pathology | January 17, 2024 | Volume: 262 | Issue: 3 | Pages: 271-288

10.1002/path.6238 | PMID 38230434 Get It

Abstract Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high‐throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi‐marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Mean Oral Cavity Organ-at-Risk Dose Predicts Opioid Use and Hospitalization during Radiotherapy for Patients with Head and Neck Tumors
Foote, Robert L. , Harmsen, W. Scott, Amundson, A., Gamez, Mauricio E. , Garces, Yolanda I. , Lester, Scott C. , McGee, L.A. , Moore, Eric J. , Wittich, Michelle A. Neben, Patel, Samir H. , Rwigema, Jean‐Claude M. , Abel, Kathryn M. Van , Yin, Linda X. , Muller, Olivia M. , Shiraishi, Satomi , Amundson, Adam C., Carr, Alan B. , Lester, Scott , McGee, Lisa A, Neben Wittich, Michelle A, Yin, Linda X , Van Abel, Kathryn M , Foote, Robert , Shiraishi, Satomi , Daniel, J. , Routman, David M.

Mayo Clinic

Cancers | January 15, 2024 | Volume: 16 | Issue: 2 | Pages: 349

10.3390/cancers16020349 | PMID 38254837 Get It

Background: Approximately 75% of all head and neck cancer patients are treated with radiotherapy (RT). RT to the oral cavity results in acute and late adverse events which can be severe and detrimental to a patient’s quality of life and function. The purpose of this study was to explore associations between RT dose to a defined oral cavity organ-at-risk (OAR) avoidance structure, provider- and patient-reported outcomes (PROs), opioid use, and hospitalization. Methods: This was a retrospective analysis of prospectively obtained outcomes using multivariable modeling. The study included 196 patients treated with RT involving the oral cavity for a head and neck tumor. A defined oral cavity OAR avoidance structure was used in all patients for RT treatment planning. Validated PROs were collected prospectively. Opioid use and hospitalization were abstracted electronically from medical records. Results: Multivariable modeling revealed the mean dose to the oral cavity OAR was significantly associated with opioid use (p = 0.0082) and hospitalization (p = 0.0356) during and within 30 days of completing RT. Conclusions: The findings of this study may be valuable in RT treatment planning for patients with tumors of the head and neck region to reduce the need for opioid use and hospitalization during treatment.
Guidance for assessment of the inflammation etiologic criterion for the GLIM diagnosis of malnutrition: A modified Delphi approach
Jensen, Gordon L. , Cederholm, Tommy , Ballesteros‐Pomar, María D. , Correia, María Isabel Toulson Davisson , Cuerda, Cristina , Evans, David C. , Fukushima, Ryoji , Ochoa, Juan B. , González, Marı́a Cristina , Gossum, A. Van , Hartono, Joseph, Manzanares, William , McMahon, M. Molly , Mendez, Yolanda , Muscaritoli, Maurizio , Nogales, Guillermo Contreras , Nyulasi, Ibolya , Phillips, Wendy , Pirlich, Matthias , Pisprasert, Veeradej , Winkler, Marion F. , Compher, Charlene , Barazzoni, Rocco , Blaauw, Renee , Gautier, Juan B Ochoa , Cuerda, Cristina , Evans, David C , Fukushima, Ryoji , Gautier, Juan Bernardo Ochoa , Gonzalez, M Cristina , Gramlich, Leah , Heymsfield, Steven B , Jager-Wittenaar, Harriët , Jayatissa, Renuka , Keller, Heather , Malone, Ainsley , Manzanares, William , Mendez, Yolanda , Mogensen, Kris M , Mori, Naoharu , Muscaritoli, Maurizio , Nogales, Guillermo Contreras , Pisprasert, Veeradej , Rothenberg, Elisabet , de van der Schueren, Marian , Shi, Han Ping , Steiber, Alison , Winkler, Marion F , Compher, Charlene , Gramlich, Leah , Heymsfield, Steven B. , Malone, Ainsley , Mogensen, Kris M.

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | January 15, 2024 | Volume: 48 | Issue: 2 | Pages: 145-154

10.1002/jpen.2590 | PMID 38221842 Get It

Abstract Background The Global Leadership Initiative on Malnutrition (GLIM) approach to malnutrition diagnosis is based on assessment of three phenotypic (weight loss, low body mass index, and reduced skeletal muscle mass) and two etiologic (reduced food intake/assimilation and disease burden/inflammation) criteria, with diagnosis confirmed by fulfillment of any combination of at least one phenotypic and at least one etiologic criterion. The original GLIM description provided limited guidance regarding assessment of inflammation, and this has been a factor impeding further implementation of the GLIM criteria. We now seek to provide practical guidance for assessment of inflammation. Methods A GLIM‐constituted working group with 36 participants developed consensus‐based guidance through a modified Delphi review. A multiround review and revision process served to develop seven guidance statements. Results The final round of review was highly favorable, with 99% overall “agree” or “strongly agree” responses. The presence of acute or chronic disease, infection, or injury that is usually associated with inflammatory activity may be used to fulfill the GLIM disease burden/inflammation criterion, without the need for laboratory confirmation. However, we recommend that recognition of underlying medical conditions commonly associated with inflammation be supported by C‐reactive protein (CRP) measurements when the contribution of inflammatory components is uncertain. Interpretation of CRP requires that consideration be given to the method, reference values, and units (milligrams per deciliter or milligram per liter) for the clinical laboratory that is being used. Conclusion Confirmation of inflammation should be guided by clinical judgment based on underlying diagnosis or condition, clinical signs, or CRP.
The Delphi Delirium Management Algorithms. A practical tool for clinicians, the result of a modified Delphi expert consensus approach.
Ottens, Thomas H. , Hermes, Carsten , Page, Valérie , Oldham, Mark , Arora, Rakesh C. , Bienvenu, O. Joseph , Boogaard, Mark van den , Caplan, Gideon A. , Hansen, Hans-Christian , Inouye, Sharon K. , Kamholz, Barbara, Maas, Matthew B. , MacLullich, Alasdair M. J. , Negro, Alessandra , Neufeld, Karin J. , Nydahl, Peter , Radtke, Finn M. , Raedt, Sylvie De , Rosenthal, Lisa , Vardy, Emma , Slooter, Arjen J. C. , Arora, Rakesh , van den Boogaard, Mark , Caplan, Gideon , Friedrich, Michaela-Elena , Hanison, James , Hansen, Hans-Christian , Inouye, Sharon K , Kotfis, Katarzyna , MacLullich, Alasdair M J , Marcantonio, Edward R , van Munster, Barbara C , Müller-Werdan, Ursula , Nydahl, Peter , Oh, Esther S , Pandharipande, Pratik , Radtke, Finn M , Raedt, Sylvie De , Spies, Claudia D , Vardy, Emma R L C , Wijdicks, Eelco Fm , Slooter, Arjen J C , Devlin, John W. , Kotfis, Katarzyna , Marcantonio, Edward R. , Morandi, Alessandro , Rosenthal, Lisa J., Sanders, Robert D. , Spies, Claudia , Wijdicks, Eelco F. M.

Mayo Clinic

Delirium | January 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.56392/001c.90652 | PMID 38348284 Get It

Delirium is common in hospitalised patients, and there is currently no specific treatment. Identifying and treating underlying somatic causes of delirium is the first priority once delirium is diagnosed. Several international guidelines provide clinicians with an evidence-based approach to screening, diagnosis and symptomatic treatment. However, current guidelines do not offer a structured approach to identification of underlying causes. A panel of 37 internationally recognised delirium experts from diverse medical backgrounds worked together in a modified Delphi approach via an online platform. Consensus was reached after five voting rounds. The final product of this project is a set of three delirium management algorithms (the Delirium Delphi Algorithms), one for ward patients, one for patients after cardiac surgery and one for patients in the intensive care unit.
Acute Coronary Syndrome Subphenotypes Based on Repeated Biomarker Measurements in Relation to Long‐Term Mortality Risk
Bakker, Marie de , Scholte, Niels T B , Oemrawsingh, Rohit M. , Umans, Victor A. , Kietselaer, Bas , Schotborgh, Carl E. , Ronner, Eelko , Lenderink, Timo , Aksoy, Ismail , Harst, Pim van der , Asselbergs, Folkert W. , Maas, Arthur , Ophuis, Anton J. Oude, Krenning, Boudewijn J., Winter, Robbert J. de , The, Salem H.K., Wardeh, Alexander J. , Hermans, Walter, Cramer, G. Etienne , Schaik, Ron HN van , Akkerhuis, K. Martijn , Kardys, Isabella , Boersma, Eric , Gasthuis, Franciscus, de Bakker, Marie , Schotborgh, Carl , van der Harst, Pim , de Winter, Robbert J , Schaik, Ron H. N. van , de Rijke, Yolanda B , Kardys, Isabella , Boersma, Eric , Lenderink, Timo , Kietselaer, Bas L J H

Mayo Clinic

Journal of the American Heart Association | January 12, 2024 | Volume: 13 | Issue: 2 | Pages: No page available

10.1161/jaha.123.031646 | PMID 38214281 Get It

Background We aimed to identify patients with subphenotypes of postacute coronary syndrome (ACS) using repeated measurements of high‐sensitivity cardiac troponin T, N‐terminal pro‐B‐type natriuretic peptide, high‐sensitivity C‐reactive protein, and growth differentiation factor 15 in the year after the index admission, and to investigate their association with long‐term mortality risk. Methods and Results BIOMArCS (BIOMarker Study to Identify the Acute Risk of a Coronary Syndrome) was an observational study of patients with ACS, who underwent high‐frequency blood sampling for 1 year. Biomarkers were measured in a median of 16 repeated samples per individual. Cluster analysis was performed to identify biomarker‐based subphenotypes in 723 patients without a repeat ACS in the first year. Patients with a repeat ACS (N=36) were considered a separate cluster. Differences in all‐cause death were evaluated using accelerated failure time models (median follow‐up, 9.1 years; 141 deaths). Three biomarker‐based clusters were identified: cluster 1 showed low and stable biomarker concentrations, cluster 2 had elevated concentrations that subsequently decreased, and cluster 3 showed persistently elevated concentrations. The temporal biomarker patterns of patients in cluster 3 were similar to those with a repeat ACS during the first year. Clusters 1 and 2 had a similar and favorable long‐term mortality risk. Cluster 3 had the highest mortality risk. The adjusted survival time ratio was 0.64 (95% CI, 0.44–0.93; P =0.018) compared with cluster 1, and 0.71 (95% CI, 0.39–1.32; P =0.281) compared with patients with a repeat ACS. Conclusions Patients with subphenotypes of post‐ACS with different all‐cause mortality risks during long‐term follow‐up can be identified on the basis of repeatedly measured cardiovascular biomarkers. Patients with persistently elevated biomarkers have the worst outcomes, regardless of whether they experienced a repeat ACS in the first year.